Zacks Investment Research Downgrades AC Immune (ACIU) to Hold

AC Immune (NASDAQ:ACIU) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report issued on Monday.

According to Zacks, “AC Immune SA is a biopharmaceutical company. It develops, discover and design novel, proprietary medicines for prevention, diagnosis and treatment of neurodegenerative diseases. The Company’s pipeline includes Crenezumab, ACI-24, Anti-Tau antibody, Morphomer Tau, Tau-PET imaging agent, Morphomer Abeta and Morphomer alpha-syn which are in clinical trial. AC Immune SA is based in Lausanne, Switzerland. “

Several other brokerages also recently commented on ACIU. BidaskClub raised shares of AC Immune from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 10th. UBS Group began coverage on shares of AC Immune in a research note on Friday, January 4th. They issued a “buy” rating and a $16.00 target price on the stock. Finally, Leerink Swann began coverage on shares of AC Immune in a research note on Monday, November 12th. They issued an “outperform” rating and a $18.00 target price on the stock. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $15.40.

Shares of NASDAQ ACIU opened at $11.68 on Monday. AC Immune has a 52 week low of $7.16 and a 52 week high of $17.40. The firm has a market capitalization of $708.02 million, a P/E ratio of -38.93 and a beta of 1.33.

AC Immune (NASDAQ:ACIU) last issued its earnings results on Tuesday, November 13th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.04. AC Immune had a negative net margin of 146.09% and a negative return on equity of 24.14%. The company had revenue of $2.34 million for the quarter, compared to the consensus estimate of $1.71 million. As a group, analysts anticipate that AC Immune will post -0.42 EPS for the current year.

A number of large investors have recently added to or reduced their stakes in ACIU. State of New Jersey Common Pension Fund D bought a new stake in AC Immune in the third quarter valued at $626,000. JPMorgan Chase & Co. bought a new stake in AC Immune in the third quarter valued at $142,000. Janus Henderson Group PLC bought a new stake in AC Immune in the third quarter valued at $13,345,000. Artal Group S.A. boosted its holdings in AC Immune by 25.0% in the third quarter. Artal Group S.A. now owns 750,000 shares of the company’s stock valued at $6,000,000 after acquiring an additional 150,000 shares in the last quarter. Finally, FMR LLC boosted its holdings in AC Immune by 28.9% in the third quarter. FMR LLC now owns 5,209,673 shares of the company’s stock valued at $41,678,000 after acquiring an additional 1,166,524 shares in the last quarter. Institutional investors and hedge funds own 29.06% of the company’s stock.

AC Immune Company Profile

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops therapeutic and diagnostic products for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.

Recommended Story: How do investors use RSI to grade stocks?

Get a free copy of the Zacks research report on AC Immune (ACIU)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for AC Immune Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AC Immune and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply